Pentapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-10. Anything still debated is marked as such rather than presented as settled.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
=== Available forms === Bicalutamide is available for the treatment of prostate cancer in most developed countries, including over 80 countries worldwide. It is available in 50 mg, 80 mg (in Japan), and 150 mg tablets for oral administration. The drug is registered for use as a 150 mg/day monotherapy for the treatment of LAPC in at least 55 countries, with the U.S. being a notable exception where it is registered only for use at a dosage of 50 mg/day in combination with castration. No other formulations or routes of administration are available or used. All formulations of bicalutamide are specifically indicated for the treatment of prostate cancer alone or in combination with surgical or medication castration. Due to the low water solubility of bicalutamide, bicalutamide in oral bicalutamide tablets is micronized to ensure small and consistent particle sizes and optimize oral bioavailability. A combined formulation of bicalutamide and the GnRH agonist goserelin in which goserelin is provided as a subcutaneous implant for injection and bicalutamide is included as 50 mg tablets for oral ingestion is marketed in Australia and New Zealand under the brand name ZolaCos CP (Zoladex–Cosudex Combination Pack).
==== Childbirth ==== Tranexamic acid is sometimes used (often in conjunction with oxytocin) to reduce bleeding after childbirth. Death due to postpartum bleeding is reduced in women receiving tranexamic acid.
=== MP for Henley: 1974–2001 === Heseltine, by now a junior minister in the Heath government, was now forced to apply for a new candidacy, often in competition with other sitting Conservative MPs whose seats were also due for abolition. He applied for Mid Sussex in competition with Ian Gilmour, but they lost to Tim Renton. He also applied for Mid-Oxfordshire but lost to Douglas Hurd. In 1972 Edward Heath attempted to persuade Heseltine, a strong supporter of his, to challenge Powellite MP Ronald Bell for the Conservative nomination for the new seat of Beaconsfield. Heseltine wrote that he was "tempted" to enter the lists at Beaconsfield, but did not actually do so. Crick writes that he reached the final shortlist of four against Bell, before being "apparently persuaded" to withdraw. Bell's campaign within the local Conservative ranks was masterminded by Hugh Simmonds, chairman of the Young Conservatives, and he narrowly won. Heseltine was one of 180 applicants for the safe Conservative seat of Henley (the constituency association of which was known as North Oxfordshire), whose MP John Hay was stepping down. He reached the final shortlist of three along with two other sitting MPs, William Shelton and Norman Fowler, and in September 1972 was selected as candidate with a clear majority at the first ballot. Part of the reason was that the Association wanted a wealthy MP who would not be distracted by the need to earn money in business as Hay had been. He maintained a constituency home in Crocker End, near Nettlebed, and still maintained a London home at Wilton Crescent.
After starting a collaboration on heart applications with Robert Weiss at Johns Hopkins, Paul returned to Johns Hopkins University in 1994, as Professor and Director of the MR Research Division. He worked on the application of MRS to measure cardiac energy metabolism in the healthy and ischemic human heart, finding that creatine kinase energy supply was compromised in heart failure, that it declined in relation to cardiac mechanical work and that it was an independent predictor of cardiac events and death. More recent work showed that a neural network based on cardiac CK metabolic parameters alone could differentiate a number of different types of cardiac disease and severity with potentially clinically useful accuracy. Paul has also worked on developing interventional MRI technology, specifically, tiny MRI detector coils that can be built into catheters to perform high resolution imaging of vessel wall and surrounding tissues; accelerated to perform real-time high resolution 'MRI endoscopy'; and potentially combined with extra-vascular therapy delivery. The earlier work led to the founding of the SurgiVision Inc start-up noted at top, and later, the development of MRI-safe implantable lead technology (licensed and sold as Avista™ by Boston Scientific Inc).
Sources: en.wikipedia.org
Very low bodyweight; Rapid weight loss, regardless of starting bodyweight; Medical comorbidities, such as infection or malabsorption; Excessive purging behaviours, including self-induced vomiting, laxative abuse, and diuretic abuse. Two of the most common indicators that RFS is occurring are low phosphate levels and low potassium levels. In these circumstances, it is recommended to start refeeding more slowly but to build up rapidly as long as RFS does not occur. Recommendations on energy requirements in the most medically compromised patients vary, from 5–10 kcal/kg/day to 1900 kcal/day. Treatment professionals must balance the risk of RFS with the risk of underfeeding, which can result in poor health outcomes for short- and long-term recovery.
==== Economic issues ==== In 2010, Larson introduced the Small Business Jobs Act of 2010, authorizing the creation of the Small Business Lending Fund Program administered by the Treasury Department to make capital investments in eligible institutions, in order to increase the availability of credit for small businesses. Larson was a strong advocate for the American Recovery and Reinvestment Act of 2009, which increased federal spending in infrastructure, education, health and energy while expanding some welfare and social security programs. His liberal stance on government spending has earned him a rating of 9% with Citizens Against Government Waste, a conservative anti-government spending interest group.
== Distribution and habitat == Coffee senna is native to the southern United States of America, Mexico and South America, but is an aggressive, pantropical weed. In Australia it is widespread but scattered in the north of Western Australia, the Northern Territory, South Australia, Queensland and New South Wales.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.